• Elanco Animal Health annual report for fiscal 2025 highlighted broad-based momentum, citing 10 straight quarters of underlying growth with gains across pet health, farm animal, and nine of its top 10 affiliates.
• Pet health posted 7% organic constant-currency growth, supported by demand for newer prescription products including Credelio Quattro and Zenrelia, alongside continued strength in retail over-the-counter offerings such as AdTab.
• Farm animal delivered 8% organic constant-currency growth, with U.S. results led by cattle and poultry; Experior moved above USD 200 million in annual revenue with nearly 80% year-over-year growth.
• Innovation remained central to strategy, with USD 892 million in innovation revenue; management pointed to more than USD 2 billion in unprobabilized potential peak sales from pipeline assets over next wave of launches.
• Focus shifted to balance-sheet repair and efficiency, with net leverage ratio reduced to 3.6x by end-2025; leverage expected to fall below 3x in 2027 as Elanco Ascend targets margin expansion and cash generation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.